Abstract:Primary central nervous system (CNS) lymphoma (PCNSL) is a rare and aggressive lymphoma that affects the CNS without other systemic involvement. High‐dose methotrexate (HDMTX)‐based regimens are recommended frontline treatment, followed by consolidation with either high‐dose chemotherapy, whole brain radiation (WBRT) +/− sequential temozolomide (TMZ), or autologous stem cell transplant (autoSCT). Despite advancements with HDMTX and rituximab, up to half of patients will relapse. Treatment for relapsed or refractory (R/R) disease varies widely as preferred regimens are not well‐established. Our study aimed to provide real‐world characterization of R/R PCNSL therapies. The secondary objective was characterization of consolidation methods after frontline treatment. This retrospective, descriptive analysis included 54 adult PCNSL patients that received a HDMTX‐based frontline regimen between 4/1/2016 and 7/1/2022. Patients receiving HDMTX for the purpose of secondary CNS lymphoma, non‐B cell origin PCNSL, and intraocular lymphoma were excluded. Thirty‐one patients (57%) received consolidation therapy with rituximab and high‐dose cytarabine (R‐HDAC), WBRT, or both. Thirteen patients (24%) proceeded with autoSCT. Twenty‐five patients had disease progression, with 17 patients receiving second line treatment. The second line treatments were WBRT (24%), clinical trial (18%), rituximab with lenalidomide (R2; 18%), re‐induction with HDMTX‐based regimens (18%), ibrutinib with rituximab (12%) and R‐HDAC (12%). Seven patients progressed, and all received third line treatment. Treatments varied, including R2; ibrutinib +/− HDMTX; rituximab, methotrexate, and cytarabine; R‐HDAC; R‐nivolumab; and WBRT. Five patients received a fourth line regimen of R +/− lenalidomide, R‐HDMTX, or nivolumab monotherapy. Regimens used for the three patients who received fifth line treatment and beyond included R‐TMZ and pembrolizumab monotherapy in addition to previously described regimens. Regimen selection is varied and highly dependent on physician preference and patient factors, including clinical trial eligibility, prior therapies, performance status, organ function, and treatment intent. Prospective clinical trials are needed to guide optimal management.

Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma

Radt-35. Patterns Of Intracranial Response And Relapse After Cns-Directed Radiotherapy (Cns-Rt) For Patients With Chemorefractory Or Progressive Secondary Cns Lymphoma (Scnsl)

1439P Brain Radiotherapy Combined with Camrelizumab and Platinum-Based Chemotherapy As First-Line Treatment for Advanced NSCLC with Brain Metastases: A Multicenter, Open-Label, Single-Arm, Phase II Study

Stereotactic Brachytherapy with Iodine-125 Seeds Plus Temozolomide Induced Complete and Durable Remission in a Patient with Recurrent Primary Central Nervous System Lymphoma.

High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom

Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post-Autologous Stem Cell Transplant

High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group

Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies

Characterizing second line and beyond therapies for primary central nervous system lymphomas

Evidence-based management of primary and secondary CNS lymphoma

Involved-Site Radiation Therapy Enables Effective Disease Control in Parenchymal Low-Grade Primary Cerebral Lymphoma

Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma

Efficacy of Salvage Radiotherapy for Relapsed/refractory Diffuse Large B-cell Lymphoma

Primary Central Nervous System Lymphoma, Treatment Outcomes - 10 Year Experience. Single Center Study

Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells

Biological Insights and Radiation–Immuno–Oncology Developments in Primary and Secondary Brain Tumors

Targets and treatments in primary CNS lymphoma

Salvage Reirradiation with Proton Beam Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer

High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis

Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy

A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma—Outcomes indicative for improved survival overtime